Shield Therapeutics (STX) is a commercial-stage pharmaceutical company delivering specialty products that address patients’ unmet medical needs in renal and gastrointestinal disorders. Its initial focus is Feraccru®, a supplement for iron deficiency with or without anaemia. Following its IPO and the EU approval of Feraccru®, both in February 2016, STX has made significant progress with its de-risked commercial strategy. Management has secured agreements with three partners with expertise in rare diseases and European market access to accelerate commercialisation of Feraccru. STX is now awaiting a game-changing FDA approval decision in Q3’19 that could unlock the US market.